{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:21:29Z","timestamp":1725150089476},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,31]]},"DOI":"10.7759\/cureus.68318","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T19:11:57Z","timestamp":1725131517000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Induced Myasthenia Gravis With Myocarditis in the Setting of Metastatic Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Phillip","family":"Taboada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remington","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zane","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto R","year":"2022","unstructured":"Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, Varricchi G. Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol. 2022, 13:804597. 10.3389\/fimmu.2022.804597","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03695-w","article-title":"Neurotoxicities associated with immune checkpoint inhibitor therapy","volume":"152","author":"Duong SL","year":"2021","unstructured":"Duong SL, Barbiero FJ, Nowak RJ, Baehring JM. Neurotoxicities associated with immune checkpoint inhibitor therapy. J Neurooncol. 2021, 152:265-77. 10.1007\/s11060-021-03695-w","journal-title":"J Neurooncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon AC","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, et al.. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:002890. 10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"ref6","article-title":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury","year":"2019","unstructured":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2019."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.125","article-title":"Rituximab in the treatment of pembrolizumab-induced myasthenia gravis","volume":"102","author":"Crusz SM","year":"2018","unstructured":"Crusz SM, Radunovic A, Shepherd S, et al.. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer. 2018, 102:49-51. 10.1016\/j.ejca.2018.07.125","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"1016","author":"Lyon AR","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018, 1016:1470-2045. 10.1016\/S1470-2045(18)30457-1","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06480-5","article-title":"Immunotherapy toxicity: identification and management","volume":"192","author":"Gumusay O","year":"2022","unstructured":"Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat. 2022, 192:1-17. 10.1007\/s10549-021-06480-5","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"135","author":"Nishimura RA","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, et al.. 2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017, 135:1159-95. 10.1161\/CIR.0000000000000503","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier M","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al.. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017, 136:2085-7. 10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285715-pembrolizumab-induced-myasthenia-gravis-with-myocarditis-in-the-setting-of-metastatic-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T19:12:02Z","timestamp":1725131522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285715-pembrolizumab-induced-myasthenia-gravis-with-myocarditis-in-the-setting-of-metastatic-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.68318","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,31]]}}}